01 What is Selank?
In plain English.
Selank is a lab-made peptide that is seven amino acids long, Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilised, longer-acting analogue of tuftsin, a natural four-amino-acid fragment of immunoglobulin G that the human body produces. The added Pro-Gly-Pro "tail" protects the peptide from being chewed up by enzymes in the blood, so it can be given as nasal drops and still reach the brain.
Selank is sold in Russia as a prescription medicine under the bioregulator-peptide framework that has no equivalent in Western pharmacovigilance. In the UK, US, EU, Australia and Canada it has no marketing authorisation and is available only as an unregulated "research chemical." That regulatory split is the most important fact about Selank: it is not unstudied, but the studies sit almost entirely inside one national research tradition.
02 How it works
The simple version, then the science.
Selank is thought to take the edge off anxiety the way a mild benzodiazepine does, by nudging the brain's GABA system, without the sedation, dependence or rebound that benzodiazepines bring. On top of that, Russian investigators report effects on serotonin, dopamine, and on brain-derived neurotrophic factor (BDNF), the same growth-factor cascade thought to underlie the lift you get from exercise or SSRIs.
Go deeper · the proposed mechanism
Mechanistic work from the Myasoedov / Andreeva / Kost groups describes Selank as a positive modulator of the GABA-A receptor system, with downstream effects on enkephalin metabolism, serotonin turnover and the expression of inflammation- and chemokine-related genes (Kolomin et al., Mol Immunol 2014). A 2021 J Clin Pharmacol review (Carter & Hartings) groups Selank with other GABAergic agents and notes that despite an interesting clinical signal, evidence outside Russia is essentially absent. Hippocampal electrophysiology studies report effects on spontaneous synaptic activity of CA1 neurons (Vyunova et al., Bull Exp Biol Med 2017). The picture is mechanistically plausible, internally consistent across the originating labs, and almost entirely unreplicated in Western neuropharmacology.
03 What it's used for
Each use graded by how strong the evidence actually is.
- ApprovedGeneralised anxiety (Russia only)Approved in Russia as a prescription anxiolytic. Russian comparative trials (e.g. Medvedev et al., Zh Nevrol Psikhiatr Korsakova 2014/2015) report efficacy in the same range as phenazepam with fewer sedative side effects. No regulator outside Russia has reviewed or endorsed this use.
- LimitedAdjunct to benzodiazepinesAnimal work (Kozlovskaya et al., Behav Neurol 2017) reports that Selank enhances the anxiety-reducing effect of diazepam in chronic-stress models. Suggests a real GABAergic interaction; not a substitute for human trial evidence.
- PreclinicalImmunomodulationAs a tuftsin analogue, Selank modulates cytokine and chemokine gene expression in rodent and cell-culture models (Kolomin et al., Mol Immunol 2014). Mechanistically interesting; no clinical immunology endpoint has been demonstrated in humans.
- PreclinicalMild nootropic / cognitive effectsRussian animal studies report effects on memory, attention and BDNF expression. Often cited online as a "smart drug"; the human cognitive data are thin and group-specific.
- AnecdotalStress, sleep and "biohacking" useWidely discussed in nootropic forums. No controlled Western data supporting these uses; user reports describe a mild, non-sedating calming effect.
04 What the evidence says
Selank sits in an unusual place on the evidence map. Unlike most "research peptides," it has been through actual human trials, including direct head-to-head comparisons with benzodiazepines for generalised anxiety, and it carries genuine regulatory approval as an anxiolytic in Russia. That is meaningfully stronger than the evidence base for, say, Epitalon or TB-500. But almost every paper traces to the Russian Academy of Sciences and its clinical collaborators (Medvedev, Myasoedov, Andreeva, Kozlovskaya, Kost, Zozulya), much of it published in Russian-language journals such as Zh Nevrol Psikhiatr Im S S Korsakova and Bull Exp Biol Med. The 2021 review in Journal of Clinical Pharmacology by Carter & Hartings is one of the few independent English-language assessments and concludes that, although Selank looks pharmacologically interesting, the trial methodology and the absence of Western replication leave its true effect size uncertain. There is no FDA-, MHRA- or EMA-registered Phase 2/3 programme. Honest position: better-evidenced than most research peptides, but still single-region literature, useful as a signal, not as a settled answer.
05 Dosing & administration
Reported in the literature, information not advice.
There is no approved Western human protocol for Selank, so no dose recommendation can be given in this jurisdiction. The Russian product is supplied as a 0.15% intranasal solution dosed in drops; cycle lengths reported in the Russian anxiety trials run from 10–14 days. Western-market "research-chemical" Selank is not the same regulated material, and the purity and concentration of online vials is not guaranteed. A qualified clinician should be consulted before considering any peptide.
06 Side effects & safety
In the published Russian trials, Selank has a reasonably clean short-term safety profile, fewer sedative, cognitive and dependence-type adverse effects than the benzodiazepine comparator phenazepam. Those trials were small, conducted by the developers, and have not been independently replicated, so the safety signal is weaker than it appears at first glance. Long-term safety in humans outside the original cohorts is essentially unknown. Products sold in Western markets as "Selank" are unregulated research chemicals, purity, sterility and dose-by-dose consistency are not guaranteed, and intranasal use of an unregulated peptide carries its own contamination risk. People who are pregnant, breastfeeding, immunocompromised, or taking other medicines, particularly benzodiazepines or other GABAergic agents, should be especially cautious.
07 Where to buy (research use only)
Vetted on quality and transparency, not an endorsement to use.
08 Legal & regulatory status
- UKNot licensed as a medicine by the MHRA. Sold only as a "research chemical", not for human use.
- USNot FDA-approved. Not on the FDA's list of bulk substances permitted for compounding. Sold as a research chemical only.
- EU / AUS / CANNo approved human medicine containing Selank. Sale for human use is unlawful in most jurisdictions; "research use only" framing is standard.
- RussiaApproved by the Russian Ministry of Health as a prescription anxiolytic / nootropic (intranasal solution). This authorisation rests on a domestic regulatory framework that has no Western equivalent.
- Sport (WADA)
09 Clinical studies & research
Primary sources. Read the science yourself.